Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Takashi WadaKazumi Mori-AnaiYutaka KawaguchiHideyuki KatsumataHidetaka TsudaMitsutaka IidaKenji ArakawaMeg J JardinePublished in: Journal of diabetes investigation (2021)
In the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events.